Financial Performance - Total revenue for Q3 2025 reached RMB 2,844,001,646.29, an increase of 1.60% compared to the same period last year[6] - Net profit attributable to shareholders decreased by 5.73% to RMB 473,012,359.77 for Q3 2025[6] - Basic earnings per share for Q3 2025 was RMB 0.52, down 3.70% year-on-year[6] - For the first nine months of 2025, the company reported operating revenue of RMB 9,115,914,290.40, a slight increase from RMB 9,081,603,788.36 in the same period of 2024, representing a growth of approximately 0.38%[28] - The operating profit for the same period was RMB 2,510,927,913.36, compared to RMB 2,315,421,100.65 in 2024, indicating an increase of about 8.44%[28] - The net profit attributable to shareholders of the parent company for the first nine months of 2025 was RMB 1,754,100,316.30, up from RMB 1,672,733,989.63 in 2024, reflecting a growth of approximately 4.86%[28] - Total comprehensive income for the period (January to September 2025) reached RMB 2,071,231,848.52, an increase from RMB 1,896,000,641.95 in the same period of 2024, representing a growth of approximately 9.2%[29] - Basic and diluted earnings per share for the period were both RMB 1.96, up from RMB 1.81 in the same period last year, representing an increase of about 8.3%[29] Assets and Liabilities - Total assets as of the end of Q3 2025 amounted to RMB 24,537,984,410.75, reflecting a 0.34% increase from the previous year[8] - Total assets as of September 30, 2025, amounted to RMB 24,537,984,410.75, slightly up from RMB 24,455,825,697.18 at the beginning of the year[26] - Current assets totaled RMB 16,572,128,734.92, compared to RMB 16,419,980,644.30 at the start of the year, showing an increase of about 0.92%[26] - Total liabilities decreased to RMB 9,170,977,356.02 from RMB 9,550,079,103.14, a reduction of approximately 3.96%[27] - The company’s total equity attributable to shareholders increased by 0.73% to RMB 13,962,841,806.50[8] - The company’s total equity attributable to shareholders increased to RMB 13,962,841,806.50 from RMB 13,862,334,189.33, reflecting a growth of about 0.72%[27] Cash Flow - Cash flow from operating activities for the year-to-date period increased by 9.42% to RMB 2,525,421,252.84[6] - Net cash flow from operating activities for the period was RMB 2,525,421,252.84, compared to RMB 2,307,915,362.28 in the previous year, indicating an increase of about 9.5%[30] - Cash inflow from investment activities skyrocketed by 993.72% to 4,935,250,581.28 RMB, primarily from the maturity of structured deposits[16] - Cash outflow from investment activities increased by 508.37% to 6,561,574,810.45 RMB, mainly due to new structured deposits[16] - The net cash flow from investment activities was -1,626,324,229.17 RMB, a decrease of 159.25% compared to the previous period[16] - Net cash flow from financing activities showed a decrease, with a net outflow of RMB 1,750,752,190.63 compared to RMB 1,912,251,596.10 in the previous year, reflecting a reduction of approximately 8.4%[31] Expenses and Investments - Development expenses rose by 61.40% to RMB 355,884,300.38, mainly due to increased investment in clinical trials for the JP1366 tablet[14] - Financial expenses increased by 244.07% to -189,000,313.28 RMB due to higher interest income from deposits[15] - Investment income rose by 88.08% to 48,706,390.01 RMB, primarily from changes in the profit and loss of associated companies[15] - Fair value changes in investment income improved by 144.49% to 2,447,091.77 RMB, reflecting fluctuations in the market value of held securities[15] - Credit impairment losses surged by 2317.48% to -7,890,079.59 RMB, mainly due to increased expected credit losses on receivables[15] - Research and development expenses for the first nine months of 2025 were RMB 683,264,467.54, compared to RMB 734,493,897.75 in 2024, indicating a decrease of approximately 6.96%[28] Shareholder Information - The total number of common shareholders at the end of the reporting period was 47,362, with 47,343 being A-share shareholders[19] - The company repurchased a total of 15,376,845 A-shares, accounting for 1.70% of the total share capital, with a total expenditure of 570,228,471.25 RMB[24] - As of September 30, 2025, the company has not repurchased any H-shares[25] Cash and Cash Equivalents - The company’s cash and cash equivalents were RMB 9,918,953,931.89, down from RMB 10,827,146,984.92 at the beginning of the year, a decrease of about 8.39%[26] - The total cash and cash equivalents at the end of the period stood at RMB 9,909,534,008.29, down from RMB 10,723,355,139.50 at the end of the previous year, a decrease of approximately 7.6%[31] - Cash received from sales of goods and services was RMB 9,744,458,934.54, slightly down from RMB 9,877,413,424.19 in the previous year, a decrease of about 1.3%[30] - The company received RMB 28,799,064.00 from investments during the period, a decrease from RMB 161,751,999.95 in the previous year, reflecting a decline of approximately 82.2%[31] - The impact of exchange rate changes on cash and cash equivalents was a decrease of RMB 56,627,486.05, compared to a decrease of RMB 21,353,488.46 in the previous year, indicating a worsening of approximately 165.7%[31]
丽珠医药(01513) - 2025 Q3 - 季度业绩